Logo

• Finished gynecological cancer (KGOG3041)

  Retrospective-REBECA: Real-world effectiveness of bevacizumab based on aurelia in platinum-resistant recurrent ovarian cancer

  • PI / PI기관 Jung-Yun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 391 person / 300 person (130.29999999999998%)

• Finished gynecological cancer (KGOG3040)

  Validation of the Functional assessment of cancer therapy - NCCN Fact Ovarian Symptom Index (NFOSI-18) & Neurotoxicity (NTX-4) for patients with ovarian cancer

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 250 person / 200 person (125.0%)

• Finished gynecological cancer (KGOG3021)

  • PI / PI기관 김용만 /
  • Registration Date / Last Update Posted 2022-04-22 / 2022-04-22
  • Current Enrollment / Estimated Enrollment 102 person / 100 person (102.0%)

• gynecological cancer (KGOG3054R)

  Retrospective-Characterization of ovarian cancer patients with somatic BRCA wild and germline BRCA mutation (SORA)

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 0 person / 300 person (0.0%)

• gynecological cancer (KGOG3036)

  NRG-GY004: Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 579 person / 561 person (103.2%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.